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Abstract Cytotoxicity of several classes of antitumor DNA 
intercalators is thought to result from disturbance of DNA 
metabolism following trapping of the nuclear enzyme DNA 
topoisomerase II as a covalent complex on DNA. Here, 
molecular interactions of the potent antitumor drug amsacrine 
(m-AMSA), an inhibitor of topoisomerase II, within living K562 
cancer cells have been studied using surface-enhanced Raman 
(SER) spectroscopy. The work is based on data of the previously 
performed model SER experiments dealing with amsacrine! 
DNA, drug/topoisomerase II and drug/DNA/topoisomerase II 
complexes in aqueous buffer solutions. The SER data indicated 
two kinds of amsacrine interactions in the model complexes with 
topoisomerase II alone or within ternary complex: non-specific 
(via the acridine moiety) and specific to the enzyme conformation 
(via the side chain of the drug). These two types of interactions 
have been both revealed by the micro-SER spectra of amsacrine 
within living K562 cancer cells. Our data suppose the specific 
interactions of amsacrine with topoisomerase II via the side chain 
of the drug (particular feature of the drug/topoisomerase II and 
ternary complexes) to be crucial for its inhibitory activity. 
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1. Introduction 
Several types of antitumor DNA intercalating agents, in- 
cluding anthraquinone (e.g., mitoxantrone, doxorubicine, 
etc.) and aminoacridine ( .g., amsacrine or m-AMSA) deriva- 
tives, have been shown to be able to trap the nuclear enzyme 
DNA topoisomerase II in the form of a cleavable complex on 
cellular DNA [1]. The mechanism by which cleavable com- 
plexes constitute biologically deleterious lesions is not clear 
but presumably involves ome disruption of DNA metabolism 
[1]. In fact, DNA topoisomerase II [2] is the eucaryotic oun- 
terpart of bacterial gyrase and can alter the topology of DNA 
in a reaction involving the introduction of a transient double 
strand break into DNA, through which an intact helix can be 
passed [3]. This reaction involves the formation of a non- 
covalent enzyme/DNA complex which is in equilibrium with 
a covalent cleavable complex [4]. Topoisomerase II poisons 
such as m-AMSA stabilize the cleavable complex, preventing 
religation of the DNA strands [4,5]. The accumulation of the 
amsacrine-stabilised cleavable ternary complexes, equestering 
strand breaks, has been shown to be an important factor in 
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the cytotoxic action of the drug [6]. Nevertheless, the molecu- 
lar mechanisms of the drug action against opoisomerase II 
are still to be defined. 
Nowadays, using of intracellular molecular probes is recog- 
nized as one of the most effective approaches in diagnostics of 
pathology and assessment of cancer treatment efficiency. The 
anticancer drugs used for cancer cells treatment can be also 
considered as molecular probes. Optical microspectroscopic 
techniques, powerful and non-destructive, are particularly 
suitable to study molecular interactions between drugs and 
their pharmacological targets within living cancer ceils [7]. 
At the molecular level, interaction of drugs with their poten- 
tial cellular targets (DNA, enzymes) can be studied using the 
high molecular selectivity and sensitivity offered by SER tech- 
nique. This kind of investigations has already enabled to pro- 
pose models (consistent with corresponding data from crystal- 
lography, NMR, etc.) of the drug-target(s) complexes for the 
numerous inhibitors of topoisomerases I and II [8 13,16]. 
The non-perturbing character of the amsacrine adsorption 
on the silver colloid, demonstrated by comparative study of 
the drug by resonance Raman and SER techniques, allowed 
us to study the complexes of this drug with DNA, topoisome- 
rase II and the ternary complexes [13]. Another advantage of 
the colloidal SER-active systems is their ability to penetrate 
through cellular membranes and, therefore, to play a role as 
an intracellular SER probe [lZl~16]. The present work is an 
extension of the studies with amsacrine to the cellular level by 
use of the confocal micro-SER technique. This novel method 
is realised by coupling of a Raman spectrometer with an op- 
tical microscope [14]. Confocal scheme of the signal filtration 
allows to achieve the spatial resolution of micron order and 
makes the approach very promising for the intracellular stud- 
ies. Finally, the structural features of drug/target complexes in 
vitro and in living cells are compared. 
2. Materials and methods 
2.1. Chemicals 
Stock solution of m-AMSA (amsacrine, Fig. 1) [17] at 10 -2 M was 
supplied by Dr. J.-F. Riou (Rh6ne-Poulenc Rorer, France) and used 
as received. Further dilution in buffer (0.02 M Tris-acetate, pH 7.3, 
2 mM NaC1, 5 mM MgSO4) was made just before the experiments. 
The use of a low ionic strength ( < 0.02) buffer allowed us to avoid the 
marked epressing of the association constant for amsacrine binding 
to DNA, observed by Wilson et al. [18] at elevated ionic strength 
(0.1). The buffer for the model complexes preparation contained 
1 mM of ATP (Sigma), because itwas shown to stimulate the cleavage 
reaction several fold [1]. 
Aqueous silver colloid was prepared by reducing silver nitrate with 
trisodium citrate as described [19] and pre-aggregated bythe addition 
of a buffer containing magnesium sulphate (final concentration of 
MgSO4 was 2.5 mM). 
pBR322 plasmid was purchased from Boehringer Mannheim. To- 
poisomerase II was purified by J.F. Riou (Rh6ne-Poulenc Rorer, 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
P11S0014-5793(96)01  41-6 
62 
France) from calf thymus according to previously published proce- 
dures [20,21]. Topoisomerase was aliquoted and stored at -70°C, 
without detectable oss of activity, in a conservation buffer containing 
10 mM Tris.HCl, pH 7.5, 20 mM 2-mercaptoethanol, 0.5 mM EDTA, 
100 mg/ml bovine serum albumin, and 50% glycerol. One unit of 
topoisomerase II corresponds to the amount of enzyme necessary to 
relax (or decatenate) 50% of 0.5 mg of pBR322 DNA, when incubated 
for 30 min at 37°C under the assay conditions. 
Preparation of the complexes for SER model measurements was as 
described before [13]. Briefly, the drug solution in the buffer was 
mixed with that of pBR322 and/or topoisomerase II, to obtain final 
molecular atios: 1 drug per 15 base pairs of DNA and 50 U of 
topoisomerase II per 0.5 ~tg of DNA. 
2.2. Cells 
The K562 human erythroleukemia cell line was established from a 
patient with chronic myelogenous leukaemia [22]. Cells (106) were 
incubated in presence of 10 l.tM m-AMSA for 1 h at 37°C and washed 
twice with buffer by centrifugation (200 x g at 4°C). Treated cells were 
then incubated with pre-aggregated silver colloid, centrifuged (5 min, 
200×g at 4°C) for a better penetration of the colloid aggregates, and 
washed with buffer to eliminate non-penetrated aggregates. Very short 
spectra recording time (about 1 min) and very low, about 20 ~tW, laser 
power at the sample both permitted to carry out the measurements 
without damage of the cells by laser radiation. 
2.3. Instrumentation 
The 514.5 nm line of a Spectra-Physics, model 2020-03, argon laser 
was used as excitation radiation in both SER (10 mW at the sample) 
and micro-SER (20 ~W under x 100 objective of microscope) meas- 
urements. No alteration of the spectra has been observed uring the 
measurements. The SER spectra for the model experiments in solu- 
tions [13] were recorded with an OMARS-89 Raman Spectrometer 
(DILOR). The micro-SER spectra for the intracellular studies were 
recorded with a confocal Raman micro-spectrometer LABRAM (DI- 
LOR) with a spatial resolution of 1 lam [14]. The microscope of the 
micro-spectrometer was equipped with a CCD camera to obtain TV 
images of the cells. The images and spectra were recorded with a 
'LABRAM' software package. 
Presented spectra of the model experiments are the result of at least 
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three independent measurements. The resulting intracellular SER 
spectrum shown is the average of more than 10 spectra recorded 
from the points with similar localisation relative to the main cellular 
compartments. 
3. Results and discussion 
Previous to the intracellular investigations, a detailed study 
of the acridine chromophore has been performed in vitro by 
resonance Raman and SER techniques [13]. The resonance 
Raman and SER spectra of amsacrine were very similar, 
when excited at the same wavelength [13]. Thus, under con- 
ditions used, the adsorption on the surface of the silver col- 
loids does not perturb the acridine chromophore. SER spec- 
tral patterns of amsacrine have been analysed by use of the 
structurally close acridine derivatives, o-AMSA and 9-ami- 
noacridine (Fig. 1A). As can be seen in the Fig. 1A, lowering 
of the symmetry of the acridine chromophore, caused by the 
appearance of the side chain (anilino rings of o- and m- 
AMSA), affects numerous Raman bands in the spectral region 
between 1605 and 1400 cm -1. However, the bands of amsa- 
crine at 1520, 1437, 1413, 1260 and 1237 cm -I  are sensitive 
not only to the presence of the anilino ring but also to the 
position of its substituents ( ee spectra 1 and 2 of meta- and 
ortho-isomers, respectively). 
These findings have been employed to interpret he SER 
data for the model complexes of the drug with plasmid 
DNA, topoisomerase II, and the topoisomerase II-mediated 
ternary cleavable complexes, prepared in aqueous buffer solu- 
tions (Fig. 1B). The main conclusions concerning these com- 
plexes can be summarised as follows [13]: 
(1) SER spectra gave indications of the intercalation of the 
planar acridine moiety of m-AMSA within DNA. The inter- 
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Fig. 1. A: Structural formulae and SER spectra of amsacrine (m-AMSA) (1), o-AMSA (2), and 9-aminoacridine (3) at 5× 10 -7 M in Tris-acet- 
ate aqueous buffer, pH 7.3. B: SER spectra of free amsacrine (1) and in the model amsacrine/DNA (2), amsacrine/topoisomerase II (3), and 
amsacrine/DNA/topoisomerase II (4) complexes. 
1. Chourpa et aLIFEBS Letters 397 (1996) 61q54 63 
A 
3 
0 
° - -  
C 
® 
C 
0 
0 
ff 
Fig. 2. A: TV image of the K562 cancer cell treated with amsacrine 
SER spectra of free amsacrine (1) and from colloid particles ituated 
calation involves a n-n  interaction between the drug and 
DNA base pairs. No contacts via the nitrogen of the acridine 
ring can be assumed, since the spectral changes for the drug/ 
DNA complexes were different from the spectral features re- 
lated to acridine deprotonation (downshift of the amsacrine 
band at 1260 cm -1 and the intensity increase of the 1560 cm -1 
band, data not shown). Arrangement of the external anilino 
ring in the minor groove of DNA is supposed to be stabilised 
by interactions between the NH group of the side chain of the 
drug and negatively charged phosphates or edges of the DNA. 
(2) SER data indicated the ability of amsacrine to interact 
via its side chain with the enzyme alone. These interactions, 
specific to enzyme conformation, .were not observed for the 
ortho-isomer of the drug. Thus, it has been shown that the 
side chain recognition as well as the spatial position and/or 
relative orientation of the acridine and anilino moieties of 
amsacrine are crucial to interact with the reaction sites of 
the enzyme. 
(3) The data of the SER experiments in solution suppose 
that in the ternary complexes of amsacrine both DNA inter- 
calation and drug/topoisomerase II interactions take place. 
The suggested model for the ternary complex of the drug is 
as follows: the acridine moiety serves as the DNA binding 
anchor, whereas the side chain of the drug, occupying the 
DNA groove, interacts with topoisomerase II. 
The next stage of this study was an attempt to validate the 
in vitro modelling by intracellular data. In order to analyse 
intracellular micro-SER spectral patterns, the micro-SER 
spectra of free amsacrine (spectrum 1 in Fig. 2B) were pre- 
viously recorded with a confocal Raman micro-spectrometer 
(see Section 2). These spectra have been obtained from iso- 
lated colloidal aggregates, incubated with the drug solution in 
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and containing silver colloidal particles (indicated with arrows), B: Micro- 
in the vicinity of the nuclea of living K562 cancer cells (2). 
buffer, in the absence of cells. The micro-SER spectra were 
similar to the SER spectra, except for a slight difference in the 
relative intensities of the Raman bands. This is due to the 
different detection systems used for the SER and micro-SER 
measurements (see Section 2). 
Then micro-SER measurements were performed on living 
K562 human erythroleukemia cells. These were treated with 
amsacrine and incubated with silver colloids as described in 
the Section 2. Visual analysis of the cells under microscope 
indicated a moderate penetration of colloid aggregates into 
the cells. The viability of cells incubated with silver colloids 
was checked by phase contrast microscopy and using 0.1% 
Trypan blue. The percentage of survival was more than 95% 
(Fig. 2A). 
On going to the colloidal aggregates within the cells, the 
micro-SER spectra of amsacrine were modified (Fig. 2B). 
Thus, we cannot assume presence of the free drug within 
the cells. It should be noted that the SER signal of amsacrine 
from small colloidal micelles located in the cytoplasm, distant 
from the nucleus, was negligible. Better micro-SER spectra of 
amsacrine were recorded from the silver aggregates, ituated 
in the vicinity of the nucleus of the living K562 cells. All these 
spectra were recorded in the same conditions: laser beam was 
focused onto the nucleus and on a silver aggregate. A large 
number of cells was analysed. From cell to cell, the spectral 
features observed for a given localisation, with respect o the 
cellular compartments, were well reproducible. This allowed 
us to analyse the spectra in order to determine the general 
spectral pattern for a given cellular compartment. 
As can be noted in the Fig. 2B, the signal-to-noise ratio and 
spectral resolution of the micro-SER spectra in the vicinity of 
the nucleus were very good. The decrease of the relative in- 
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tensity of the bands at 1605, 1560, 1520, 1413, 1260 cm 1 was 
clearly pronounced. It is very important o underline that 
these spectral modifications (Fig. 2B) were very similar to 
those in the SER spectra of amsacrine in the model complexes 
in the presence of topoisomerase II (Fig. I B). 
As was described before based on the data of the SER 
experiments [13], two kinds of amsacrine/target in eractions 
in the model complexes are assumed: (1) interactions via the 
acridine moiety, indicated by loss of the intensity of the bands 
at 1560, 1413 and 1260 cm 1. These have been observed for 
amsacrine and for its ortho-isomer in the complexes with 
DNA and/or topoisomerase II (Fig. IB). The interactions of 
this kind are not specific to the enzymatic onformation, since 
they have been observed for the drug in the presence of de- 
activated topoisomerase II [13] (data not shown). (2) interac- 
tions via the side chain of the drug, indicated by decrease of 
the bands at 1604 and 1520 cm -1. These have been observed 
for amsacrine (and not for o-AMSA) in the presence of active 
topoisomerase II (alone or within ternary complexes, pectra 3
and 4 in Fig. 2, respectively). These interactions are specific to 
the enzyme conformation, since they disappeared when the 
complexes were prepared with deactivated topoisomerase II 
[13]. 
The observation of both (1) and (2) spectral features in the 
intracellular micro-SER spectra (Fig. 2B) indicates both spe- 
cific and non-specific molecular interactions of amsacrine 
within living K562 cancer cells. Although these two types of 
interactions are both involved in the molecular mechanisms of 
action of amsacrine, however, specific ones should play a cru- 
cial role in the inhibitory activity of the drug, since they form 
a particular feature of the drug/topoisomerase II and ternary 
complexes and are not observed for the inactive ortho-isomer 
of the drug. 
It is noteworthy that the only feature differing the SER 
spectra of amsacrine within drug/DNA/topoisomerase II com- 
plexes (spectrum 4 in Fig. 1B), from those of drug/topoisome- 
rase II (spectrum 3 in Fig. 1B), was a less pronounced e- 
crease of the intensity ratio of the 1605/1595 cm -1 bands in 
the ternary complexes. From this point of view, the intracel- 
lular micro-SER spectra re closer to those of the drug/topoi- 
somerase II complexes. However, the described feature is too 
slight to be indicative of the preference for the amsacrine/ 
topoisomerase II complexes rather than ternary ones as cor- 
responding to the intracellular data. In fact, although the 
biological activity of amsacrine is supposed to be realised by 
stabilisation of cleavable ternary complexes [1,5], our data do 
not exclude that the drug/topoisomerase II direct interactions 
could be responsible for inhibition of this nuclear enzyme. 
For this reason, further investigations of the interaction of 
m-AMSA and other DNA intercalating and non-intercalating 
topoisomerases poisons with the components of the cellular 
nucleus and the cytoplasm, performed on living cells, are con- 
sidered important for the elucidation of biological effects of 
these drugs in cytotoxicity, differentiation and programmed 
cell death or apoptosis. These studies could also help to un- 
derstand the drug resistance mechanisms which lead to differ- 
ent responses in clinical chemotherapy. 
Our data demonstrate great capabilities of the micro-SER 
technique as a non-destructive intracellular probe and support 
the model experiments as a good assumption of the intracel- 
lular molecular interactions. 
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